Imprivata has partnered with Keyo to deliver a contactless version of its PatientSecure patient identification platform. The solution is intended to alleviate public safety concerns and reduce the risk of spreading COVID-19 in clinical environments.
PatientSecure uses palm vein recognition to securely link a patient’s medical records to their biometric information. The technology speeds up the patient identification process during an appointment, and ensures that doctors always have easy access to the proper documentation.
However, previous versions of the platform utilized a contact-based palm vein scanner, making it a potential point of transmission during the pandemic. Imprivata has insisted that the palm scanner is safe when cleaned properly, but was obviously aware of those concerns and has taken steps to address them. The new Keyo scanner has an antimicrobial copper coating, and eliminates the need to make physical contact with the device to support the ongoing digital transformation efforts in the healthcare industry.
“Patients are expecting a safe and streamlined experience as they return to physical locations for medical care amidst the COVID-19 pandemic,” said Imprivata Chief Medical Officer Sean Kelly. “We’re pleased to help our customers meet those expectations with the touchless biometric identification, improved patient matching, and workflow optimization offered with the latest version of PatientSecure.”
“Touchless patient identification delivers value for healthcare right now, when it is needed most,” added Keyo CEO Jaxon Klein.
Imprivata was listed as the top Client Satisfaction for Identity Governance solution in the 2020 Black Book Survey over the summer. The company has since unveiled a new Digital Identity Framework that was built to help healthcare organizations that need to create a comprehensive digital identity strategy.
Keyo, meanwhile, recently said that its palm recognition technology is compatible with Amazon’s palm scanning system for retail outlets.
–
October 13, 2020 – by Eric Weiss
Follow Us